4-bromo-3-methoxy-1H-pyrazole | 1147011-26-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-bromo-3-methoxy-1H-pyrazole
• 英文别名: 4-bromo-5-methoxy-1H-pyrazole
• CAS: 1147011-26-4
• 化学式: C₄H₅BrN₂O
• 分子量: 177.0
• InChiKey: PUFHRMDRFZPMHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  甲基乙烯砜 、 4-bromo-3-methoxy-1H-pyrazole 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 以400 mg的产率得到4-Bromo-3-methoxy-1-(2-methylsulfonylethyl)pyrazole
  参考文献：
  名称：

  WO2024059169A1

  摘要：

  公开号：
• 作为产物：
  描述：

  3-甲氧基-1H-吡唑 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以400 mg的产率得到4-bromo-3-methoxy-1H-pyrazole
  参考文献：
  名称：

  WO2024059169A1

  摘要：

  公开号：

文献信息

• [EN] POLO LIKE KINASE 4 INHIBITORS<br/>[FR] INHIBITEURS DE KINASE DE TYPE POLO 4
  申请人：ORIC PHARMACEUTICALS INC

  公开号：WO2022240876A1

  公开（公告）日：2022-11-17

  Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Formula (I)

  本文披露了公式（I）的化合物或其药学上可接受的盐，它们是Polo Like Kinase 4（PLK4）的抑制剂。本文还披露了包含公式（I）的化合物或其药学上可接受的盐以及一个或多个药学上可接受的辅料的制药组合物。本文还披露了治疗需要的患者的癌症的方法，包括向患者投与公式（I）的化合物或其药学上可接受的盐的量。公式（I）:
• NOVEL COMPOUNDS AS CK2 INHIBITORS
  申请人：[en]CAMBRIDGE ENTERPRISE LIMITED

  公开号：WO2024052702A1

  公开（公告）日：2024-03-14

  Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
• [EN] PURINES AND METHODS OF THEIR USE<br/>[FR] PURINES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：[en]KINETA, INC.

  公开号：WO2023107552A2

  公开（公告）日：2023-06-15

  Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
• CN117069715
  申请人：——

  公开号：——

  公开（公告）日：——